ClinicalTrials.Veeva

Menu

Prevalence of Chronic Kidney Disease and Its Association With Clinical Outcome in Patients With Coronary Heart Disease

P

Peking University

Status

Unknown

Conditions

Chronic Kidney Disease
Coronary Heart Disease

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT02509013
WI198103

Details and patient eligibility

About

This is a prospective, multi-center, hospital-based observational study. The aim of the study is to evaluate the prevalence of chronic kidney disease in patients with stable coronar heart disease.

Full description

The primary aim of the study is to evaluate the prevalence of chronic kidney disease(CKD) in patients with stable coronary heart disease. The secondary aims include: 1. To evaluate the awareness of CKD in patients with stable coronary heart disease. 2. To find out risk factors that is associated with CKD in these patients. 3. To evaluate the association between CKD and cardiovascular events during one-year's follow-up. Based on sample size estimation, the plan is to recruit 10000 patients from 100 centers. Patients who participate the study will finish one-year's follow up (0 day, 6 months and 12 months after recruitment). During the baseline visit, patients' demographic characters will be collected, and laboratory tests will be performed for urinalysis, renal function, hepatic function, etc. During the 6 months' follow up, MACE(Major adverse cardiovascular events) will be recorded through phone or face to face interview between investigators and patients. MACE include all-cause mortality, cardiovascular mortality, non-fatal myocardial infarction, documented re-hospitalization for unstable angina pectoris, and coronary revascularization (including percutaneous coronary intervention and CABG). During the 12 month's follow up, MACE will be recorded, and laboratory tests will be performed again.

Enrollment

10,000 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age≥18 years.

  • Patients with clinical evidence of stable coronary heart disease, who meet at least one of the following three criterias:

    a. Stable coronary heart disease with objective evidence of atherosclerosis, either coronary angiography shows ≥50% stenosis of at least one of the coronary main stems or first-level branches, or typical exertional angina pectoris with positive stress tests(ECG stress test, echocardiograph stress test, or stress radionuclide myocardial imaging). b Diagnosed of myocardial infarction at least 3 months before recruitment. c.Coronary revascularization(PCI or CABG) at least 3 months before recruitment.

  • Informed consent signed by patients or legal guardians.

  • Willing to and capable of being followed up for 1 year.

Exclusion criteria

  • Non-atherosclerotic coronary heart disease
  • Deterioration of heart failure during the past 3 months
  • Exposed to contrast agent during the past one month.
  • History of amputation
  • Pregnancy
  • Female patients in menstrual period(still eligible after menstrual period)
  • Organ failure other than heart failure and kidney failure
  • Comorbid other diseases, and life expectancy <1 year
  • Considered not fit for the study due to other reasons, including but not restricted to : a. Severe infection; b. Acute kidney injury.

Trial contacts and locations

1

Loading...

Central trial contact

Jie Jiang, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems